CORD-19:038354e8830fe01feb621a12e8a8c467a15b6354 / 151989-152348 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/038354e8830fe01feb621a12e8a8c467a15b6354","sourcedb":"CORD-19","sourceid":"038354e8830fe01feb621a12e8a8c467a15b6354","text":"In phase II studies, in which volunteers were inoculated with either HRV39 or Hanks, subjects were randomized to receive intranasal ruprintrivir (8 mg) or placebo sprays as prophylaxis (2 or 5 times daily (2 times per day or 5 times per day) for 5 days) starting 6 h before infection or as treatment (5 times per day for 4 days) starting 24 h after infection.","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T948","span":{"begin":0,"end":359},"obj":"Sentence"},{"id":"T33516","span":{"begin":0,"end":359},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"TextSentencer_T948","pred":"source","obj":"CORD-19-Sentences"},{"subj":"T33516","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T16","span":{"begin":0,"end":359},"obj":"Sentence"}],"attributes":[{"subj":"T16","pred":"source","obj":"CORD-19_Custom_license_subset"}]},{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T817","span":{"begin":274,"end":283},"obj":"Disease"},{"id":"T818","span":{"begin":349,"end":358},"obj":"Disease"}],"attributes":[{"id":"A817","pred":"mondo_id","subj":"T817","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A818","pred":"mondo_id","subj":"T818","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"subj":"T817","pred":"source","obj":"CORD-19-PD-MONDO"},{"subj":"T818","pred":"source","obj":"CORD-19-PD-MONDO"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#ecb893","default":true},{"id":"CORD-19_Custom_license_subset","color":"#9e93ec"},{"id":"CORD-19-PD-MONDO","color":"#a1ec93"}]}]}}